<SEC-DOCUMENT>0001104659-26-018128.txt : 20260220
<SEC-HEADER>0001104659-26-018128.hdr.sgml : 20260220
<ACCEPTANCE-DATETIME>20260220160224
ACCESSION NUMBER:		0001104659-26-018128
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20260220
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260220
DATE AS OF CHANGE:		20260220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FENNEC PHARMACEUTICALS INC.
		CENTRAL INDEX KEY:			0001211583
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32295
		FILM NUMBER:		26659724

	BUSINESS ADDRESS:	
		STREET 1:		PO BOX 13628
		STREET 2:		68 TW ALEXANDER DRIVE
		CITY:			RESEARCH TRIANGLE PARK
		STATE:			NC
		ZIP:			27709
		BUSINESS PHONE:		(919) 636-4530

	MAIL ADDRESS:	
		STREET 1:		PO BOX 13628
		STREET 2:		68 TW ALEXANDER DRIVE
		CITY:			RESEARCH TRIANGLE PARK
		STATE:			NC
		ZIP:			27709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FENNEC PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20140903

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADHEREX TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20021223
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>fencf-20260220x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.2.0.5 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 2/20/2026 8:23:21 PM -->
<!-- iXBRL Library version: 1.0.9448.42501 -->
<!-- iXBRL Service Job ID: 00000000-0000-0000-0000-000000000000 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:fencf="http://adherex.com/20260220" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title>FENNEC PHARMACEUTICALS INC._February 20, 2026</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" name="dei:EntityCentralIndexKey" id="Tc_jysIPrjWQUmNBdilL3KD_g_1_1">0001211583</ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" name="dei:AmendmentFlag" id="Tc_FJcPCylevEq7qYpIC16WvQ_2_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="fencf-20260220.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001211583</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-20</xbrli:startDate><xbrli:endDate>2026-02-20</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="filing_1"></a><a id="doc_1_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;border-bottom:1px solid #000000;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><a id="_c4ab4dee_5bf1_47d1_badd_0ec511e69925"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form </b><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" name="dei:DocumentType" id="Narr_vGxwr5Ih10a4zmplVODjDw"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Current Report</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_nFwD3d3YOUm9qWid6O9SJA"><b style="font-weight:bold;">February 20, 2026</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" name="dei:EntityRegistrantName" id="Narr_kjci57_x1Eeh-Ho9f8lm2Q"><b style="font-weight:bold;">FENNEC PHARMACEUTICALS INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" name="dei:EntityFileNumber" id="Narr_Y9Dm7YPUjU2eNNkX6i0Qjg"><b style="font-weight:bold;">001-32295</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Commission File Number)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p><a id="_708ebdf6_9201_4cd9_ad33_e4b35eaf159f"></a><a id="Tc_Y2NVoVGriECh3OYpWO-0Kg_2_0"></a><a id="Tc_mEscChMjwUqzoz7gMUaEmA_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="Tc_-ww0H-dDiUWR-DJiR5xinw_1_0"><b style="font-weight:bold;">British Columbia, Canada</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" name="dei:EntityTaxIdentificationNumber" id="Tc_6p_mKrcc80ahMQHuoIGM0Q_1_2"><b style="font-weight:bold;">20-0442384</b></ix:nonNumeric></p></td></tr><tr style="height:24.75pt;"><td style="vertical-align:top;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(State or other jurisdiction of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">incorporation)</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><a id="_e090d7dc_684f_44cb_97fb_58d583532ff3"></a><a id="Tc_596IJtSz5USW_JYlzb_ANA_1_0"></a><a id="Tc_y4ZQ0a3LukG9tv6bJd-3oA_2_0"></a><a id="Tc_O6C68aWzv02MI3rUAPgTkw_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:24.75pt;"><td style="vertical-align:top;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" name="dei:EntityAddressAddressLine1" id="Narr_AWNs0ZUP006cF3rLI1zqLw"><b style="font-weight:bold;">PO Box 13628</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" name="dei:EntityAddressAddressLine2" id="Narr_hrQtaZdFd0CTs4mRenxE1g"><b style="font-weight:bold;">68 TW Alexander Drive</b></ix:nonNumeric><b style="font-weight:bold;">,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" name="dei:EntityAddressCityOrTown" id="Narr_aKhZ2Y1Id0ik4L78TUCWtQ"><b style="font-weight:bold;">Research Triangle Park</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" name="dei:EntityAddressStateOrProvince" id="Narr_p-qFiLksNk6ENvxJ80NCbw"><b style="font-weight:bold;">NC</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" name="dei:EntityAddressPostalZipCode" id="Tc_iZfK511Yr0uNIyKC9_Aq0Q_1_2"><b style="font-weight:bold;">27709</b></ix:nonNumeric></p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:47.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code:</b> (<ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" name="dei:CityAreaCode" id="Narr_Qx9CzwU8JEmfvqfWMVAgMQ"><b style="font-weight:bold;">919</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" name="dei:LocalPhoneNumber" id="Narr_tzHqPynZR0qIIfl0QNyyiw"><b style="font-weight:bold;">636-4530</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><a id="_605244ff_014d_4223_aa42_d6275a578658"></a><a id="Tc_vcwyGngiBkeeQF9-8-ZR3w_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:97.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_2nK8ANSfrk-GDcv2Wm9qFw_1_1"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:97.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><a id="_fab354cc_01e2_4748_9401_103a3c762fc2"></a><a id="Tc_BGcnKSzzVke00ayrzK7UrA_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:97.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_PSfcH160FESbJQyUWEsUbg_1_1"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:97.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><a id="_bf069743_f10a_419b_8c12_d2934f366092"></a><a id="Tc_947XMKy13k2Y4QeK7OVowA_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:97.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_UsGs3plNJkWq9yZxenpSZQ_1_1"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:97.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><a id="_ba6b5d52_6143_4356_af7f_19f2aff75a6e"></a><a id="Tc_gpq5rF59skmEd_we2Umrfw_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:97.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_joA9xlOGcUGwLNDJc8CRJQ_1_1"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:97.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160; &#160; &#160; &#160; &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Securities registered pursuant to Section 12 of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2a233d4b_687d_4358_bb03_f1831b91a917"></a><div style="padding-left:0.4pt;"><a id="Tc_7UrO_7Zs0UuEwDMQn4vPLw_1_0"></a><a id="Tc_sDPHBIUl-E6VIMtAUz5S1A_1_1"></a><a id="Tc_FKkIQmvK4kWru_lDf-Lr9w_1_2"></a><a id="Tc_Mn0x9hPTAUadpzmFP5fO1g_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:27.3pt;"><td style="vertical-align:bottom;width:33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:1.1pt 1.1pt 0pt 1.1pt;">Title of each class</p></td><td style="vertical-align:bottom;width:33.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:1.1pt 1.1pt 0pt 1.1pt;">Trading symbol(s)</p></td><td style="vertical-align:bottom;width:33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:1.1pt 1.1pt 0pt 1.1pt;">Name of each exchange on which registered</p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:bottom;width:33%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:1.1pt 1.1pt 0pt 1.1pt;"><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" name="dei:Security12bTitle" id="Tc_G_H7yTn_606kgQL1W71HWw_2_0">Common shares, no par value</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:1.1pt 1.1pt 0pt 1.1pt;"><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" name="dei:TradingSymbol" id="Tc_9hmkBlNIJ0iZhwHUYTQF2A_2_1">FENC</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:1.1pt 1.1pt 0pt 1.1pt;"><ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Narr_4kj_swpFQEGc_mZoyAkKSA">Nasdaq</ix:nonNumeric> Capital Market</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 56.1pt 0pt 13.2pt;">Emerging growth company&#160;&#160;&#160;<ix:nonNumeric contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_wcDTKnRweESa8yfmnC8spQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;</p><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;padding-bottom:0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;border-bottom:1px solid #000000;margin:0pt;">&#160;</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><a id="part_1_2_1"></a><a id="item_1_30_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><a id="_bb8161f6_82f2_4f08_832a_3fa88766c46b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item 8.01.</b></p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Other Events.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">On February 20, 2026, Fennec Pharmaceuticals Inc. (the &#8220;Company&#8221;) announced that real-world data supporting the potential use of PEDMARK<sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (sodium thiosulfate injection) in adults with head and neck cancers were presented at the 2026 Multidisciplinary Head and Neck Cancers Symposium held February 19&#8211;21, 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">The data, derived from a retrospective review of 15 adult patients, indicated that PEDMARK<sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> administered at least six hours after cisplatin was feasible and well tolerated, with no disruption to cisplatin-based treatment delivery observed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">PEDMARK<sup style="font-size:9pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is approved in the United States to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. Its safety and efficacy in adults with head and neck cancers have not been established.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">The information contained in this Item 8.01, including Exhibit 99.1 attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor incorporated by reference into any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:27.5pt;margin:0pt;">&#160;&#160;</p><a id="part_1_2_2"></a><a id="item_1_47_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:27.5pt;margin:0pt;">&#160;</p><a id="_8b6988b8_983b_4464_ae76_432fc85a9715"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:27.5pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item 9.01</b></p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Financial Statements and Exhibits.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:41.8pt;text-indent:-41.8pt;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:89.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(d)</p></td><td style="vertical-align:top;width:89.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Exhibits.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit No.</span></p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 5.5pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Description</span></p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 5.5pt;">&#160;</p></td></tr><tr style="height:16.65pt;"><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exhibit 99.1</p></td><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 5.5pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="fencf-20260220xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release dated February 20, 2026</span></a></p></td></tr><tr style="height:16.65pt;"><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exhibit 104</p></td><td style="vertical-align:bottom;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 5.5pt;">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;border-bottom:1px solid #000000;margin:0pt;">&#160;</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="part_1_2_3"></a><a id="_439a8767_eba5_4fa6_af3f_489996de6169"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:27.35pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:27.5pt;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">FENNEC PHARMACEUTICALS INC.</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 5.5pt 0pt 5.5pt;">&#160;</p></td><td style="vertical-align:top;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 5.5pt 0pt 5.5pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 5.5pt 0pt 5.5pt;">&#160;</p></td><td style="vertical-align:top;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 5.5pt 0pt 5.5pt;">&#160;</p></td></tr><tr style="height:12.4pt;"><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date February 20, 2026</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 5.5pt 0pt 5.5pt;">By:</p></td><td style="vertical-align:top;width:48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 5.5pt 0pt 5.5pt;">/s/ Robert Andrade</p></td></tr><tr style="height:24.75pt;"><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 5.5pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 14.3pt 0pt 14.3pt;">Robert Andrade</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 14.3pt 0pt 14.3pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>fencf-20260220xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 2/20/2026 08:23:20 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;"><img src="fencf-20260220xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:55.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:98.23pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:14pt;font-weight:bold;text-transform:uppercase;">FENNEC PHARMACEUTICALS PRESENTS REAL WORLD DATA SUPPORTING THE integration AND CLINICAL USE OF Pedmark</b><sup style="font-size:10.5pt;font-weight:bold;text-transform:uppercase;vertical-align:top;">&#174;</sup><b style="font-size:14pt;font-weight:bold;text-transform:uppercase;"> IN TREATING ADULTS WITH HEAD &amp; nECK CANCERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0pt 18pt;"><i style="font-size:12pt;font-style:italic;">&#8211; Administration of PEDMARK</i><sup style="font-size:9pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-size:12pt;font-style:italic;"> Approximately Six Hours After Cisplatin was Shown to Be Safe &amp; Easily Integrated into Care for Adults with Head &amp; Neck Cancers (HNC) &#8211;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0pt 18pt;"><font style="font-size:12pt;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0pt 18pt;"><i style="font-size:12pt;font-style:italic;">&#8211; Early Signals of Hearing Preservation Highlight the Potential of PEDMARK</i><sup style="font-size:9pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-size:12pt;font-style:italic;"> to Address Cisplatin-Induced Hearing Loss, a Critical Survivorship Gap, Without Compromising Cisplatin&#8217;s Established Antitumor Activity &#8211;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0pt 18pt;"><font style="font-size:12pt;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0pt 18pt;"><i style="font-size:12pt;font-style:italic;">&#8211; Majority of High-Risk Patients Receiving PEDMARK</i><sup style="font-size:9pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-size:12pt;font-style:italic;"> Demonstrated No Measurable Hearing Loss During or After Treatment Despite Prevalence of Baseline Hearing Impairment &#8211;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0pt 18pt;"><font style="font-size:12pt;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Research Triangle Park, NC, February 20, 2026</b><font style="font-size:12pt;"> &#8211; Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced new real world data supporting potential use of PEDMARK</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-size:12pt;"> (sodium thiosulfate injection) in adults with head and neck cancers were presented as a digital poster at the 2026 Multidisciplinary Head and Neck Cancers Symposium (MHNCS) in Palm Desert, CA from February 19 &#8211; 21, 2026.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Findings from a multi-institutional retrospective review of 15 adults with head and neck cancers (HNC) showed that PEDMARK</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-size:12pt;"> could be safely given &#8805;six hours after cisplatin dosing and was easy to incorporate into the real-world care plan for adults with HNC. This strict post-cisplatin timing is a validated approach intended to preserve cisplatin antitumor activity and no disruption to curative-intent cisplatin-based treatment delivery was observed as part of the study review.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">&#8220;Head and neck cancer is one of the most common cancers globally,</font><sup style="font-size:9pt;vertical-align:top;"><a style="vertical-align:super;" href="#endnote-2">i</a></sup><font style="font-size:12pt;"> underscoring why these results are encouraging for clinicians. Importantly, the data support the potential of the drug to address cisplatin-induced hearing loss &#8211; a major and often overlooked survivorship challenge &#8211; without compromising cisplatin&#8217;s proven antitumor activity,&#8221; said Maria A. Velez, M.D., M.S., coauthor of the study and clinical instructor&#160;in the Division of Hematology/Oncology at UCLA Health. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">&#8220;Cisplatin-induced hearing loss remains one of the most underrecognized yet deeply consequential toxicities associated with cancer treatment,&#8221; said Leslie Worona, FNP-BC, OCN, coauthor of the study and oncology nurse practitioner at Mount Sinai Hospital. &#8220;The findings that most patients &#8211; even those with high rates of pre-existing hearing impairment &#8211; who received PEDMARK</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-size:12pt;"> experienced no measurable hearing loss during or after treatment supports further exploration of PEDMARK</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-size:12pt;"> use in additional patient populations and tumor types such as HNC.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">PEDMARK was shown to be well tolerated, with only isolated, self-limited infusion events and no grade 3 or 4 toxicities. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">&#8220;These new findings are critical to demonstrating the feasibility, scalability and long-term value of PEDMARK</font><sup style="font-size:9pt;vertical-align:top;">&#174; </sup><font style="font-size:12pt;">beyond those studied in our pivotal clinical program,&#8221; said Pierre S. Sayad, PhD, M.S., chief medical officer of Fennec Pharmaceuticals. &#8220;Additionally, these data may help to strengthen the case for broader clinical adoption in a sizable patient population at high risk for permanent hearing loss.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">The study&#8217;s primary endpoint evaluated feasibility, defined by timing adherence (&#8805;6 hours) and operational metrics, including administration setting (home vs. clinic infusion) and chair time for infusion-center dosing. Secondary endpoints included infusion-related events, need for antiemetic escalation, and completion of on-treatment and post-treatment audiology assessments. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">PEDMARK</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-size:12pt;"> is currently approved for pediatric patients one month of age and older with localized, non-metastatic solid tumors, and is also recognized by the National Comprehensive Cancer Network with a 2A recommendation for use in adolescent and young adult patients.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;background:#ffffff;">About Cisplatin-Induced Ototoxicity </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;background:#ffffff;">Cisplatin and other platinum-based chemotherapies are widely used to treat solid tumors and have been vital in improving survival rates. &#160;Unfortunately, these life-saving treatments often result in permanent, irreversible hearing loss, also known as ototoxicity.</font><sup style="font-size:9pt;vertical-align:top;background:#ffffff;"><a style="vertical-align:super;" href="#endnote-3">ii</a></sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;background:#ffffff;">Hearing loss from cisplatin treatment is not rare. Studies show that between 60-90% of patients treated with cisplatin may develop hearing loss, depending upon the dose and duration of chemotherapy</font><sup style="font-size:9pt;vertical-align:top;background:#ffffff;"><a style="vertical-align:super;" href="#endnote-4">iii</a></sup><font style="font-size:12pt;background:#ffffff;">. Many of those treated with cisplatin will require lifelong hearing aids or cochlear implants, which can be helpful for some, but do not reverse the hearing loss and can be costly over time.</font><sup style="font-size:9pt;vertical-align:top;background:#ffffff;"><a style="vertical-align:super;" href="#endnote-5">iv</a></sup><font style="font-size:12pt;background:#ffffff;"> Treatment-induced hearing loss can reduce quality of survivorship as it impacts many aspects of life, such as speech and language skills, academic performance, social-emotional development, &#160;career potential &#160;and the ability to live independently.</font><sup style="font-size:9pt;vertical-align:top;background:#ffffff;"><a style="vertical-align:super;" href="#endnote-6">v</a>,<a style="vertical-align:super;" href="#endnote-7">vi</a></sup><font style="font-size:12pt;background:#ffffff;"> While audiologic monitoring is recommended to help manage ototoxicity, it is currently underutilized in certain cancer patient populations.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">PEDMARK</b><sup style="font-size:9pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-size:12pt;font-weight:bold;">&#160;(sodium thiosulfate injection)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">PEDMARK</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-size:12pt;"> is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients 1 month of age and older with localized, non-metastatic, solid tumors. It is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is also the first and only therapeutic agent with proven efficacy and safety data with an established dosing regimen, across two open-label, randomized Phase 3 clinical studies, the Children&#8217;s Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. &#160; </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Additionally, PEDMARK is recommended for the adolescent and young adult (AYA) population by the National Comprehensive Cancer Network, or NCCN, with a 2A endorsement. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;background:#ffffff;">Approximately 500,000 patients in the U.S. are diagnosed annually with cancers that could be treated with a platinum-based chemotherapy.</font><sup style="font-size:9pt;vertical-align:top;background:#ffffff;"><a style="vertical-align:super;" href="#endnote-8">vii</a>,<a style="vertical-align:super;" href="#endnote-9">viii</a></sup><font style="font-size:12pt;background:#ffffff;"> The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of those treated will require lifelong hearing aids. Until the FDA approval of PEDMARK, there were no preventative agents for this hearing loss. Patients with hearing loss resulting from cancer treatment have a statistically significant worse quality of life compared with peers who have no hearing loss.</font><sup style="font-size:9pt;vertical-align:top;background:#ffffff;"><a style="vertical-align:super;" href="#endnote-10">ix</a><a style="vertical-align:super;" href="#endnote-11">x</a></sup><font style="font-size:12pt;background:#ffffff;"> </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;background:#ffffff;">PEDMARK has been studied by co-operative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, COG ACCL0431 and SIOPEL 6. Both studies have been completed. The COG ACCL0431 protocol enrolled childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, medulloblastoma, and other solid tumors. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;background:#ffffff;">Indications and Usage</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;background:#ffffff;">PEDMARK</font><sup style="font-size:9pt;vertical-align:top;background:#ffffff;">&#174;</sup><font style="font-size:12pt;background:#ffffff;"> (sodium thiosulfate injection) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Limitations of Use</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Important Safety Information &#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">PEDMARK is contraindicated in patients with history of a severe hypersensitivity to sodium thiosulfate or any of its components.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Hypersensitivity reactions occurred in 8% to 13% of patients in clinical trials. Monitor patients for hypersensitivity reactions. Immediately discontinue PEDMARK and institute appropriate care if a hypersensitivity reaction occurs. Administer antihistamines or glucocorticoids (if appropriate) before each subsequent administration of PEDMARK. PEDMARK may contain sodium sulfite; patients with sulfite sensitivity may have hypersensitivity reactions, including anaphylactic symptoms and life-threatening or severe asthma episodes. Sulfite sensitivity is seen more frequently in people with asthma.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">PEDMARK is not indicated for use in pediatric patients less than 1 month of age due to the increased risk of hypernatremia or in pediatric patients with metastatic cancers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Hypernatremia occurred in 12% to 26% of patients in clinical trials, including a single Grade 3 case. Hypokalemia occurred in 15% to 27% of patients in clinical trials, with Grade 3 or 4 occurring in 9% to 27% of patients. Monitor serum sodium and potassium levels at baseline and as clinically indicated. Withhold PEDMARK in patients with baseline serum sodium greater than 145 mmol/L.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Monitor for signs and symptoms of hypernatremia and hypokalemia more closely if the glomerular filtration rate (GFR) falls below 60 mL/min/1.73m</font><sup style="font-size:9pt;vertical-align:top;">2</sup><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Administer antiemetics prior to each PEDMARK administration. Provide additional antiemetics and supportive care as appropriate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">The most common adverse reactions (&#8805;25% with difference between arms of &gt;5% compared to cisplatin alone) in SIOPEL 6 were vomiting, nausea, decreased hemoglobin, and hypernatremia. The most common adverse reaction (&#8805;25% with difference between arms of &gt;5% compared to cisplatin alone) in COG ACCL0431 was hypokalemia.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Please see full Prescribing Information for PEDMARK</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-size:12pt;"> at: </font><font style="font-size:12pt;">www.PEDMARK.com</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;background:#ffffff;">About&#160;Fennec Pharmaceuticals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-size:12pt;"> to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI</font><sup style="font-family:'Symbol';font-size:9pt;vertical-align:top;background:#ffffff;">&#210;</sup><font style="font-size:12pt;">. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">In&#160;March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize&#160;PEDMARQSI</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-size:12pt;">&#160;in&#160;Europe,&#160;U.K., Australia and&#160;New Zealand. PEDMARQSI is now commercially available in the U.K. and Germany. &#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;">For more information, please visit </font><font style="font-size:12pt;">www.fennecpharma.com</font><font style="font-size:12pt;"> and follow on </font><font style="font-size:12pt;">LinkedIn</font><font style="font-size:12pt;">. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Forward Looking Statements</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><i style="font-size:12pt;font-style:italic;">Except for historical information described in this press release, all other statements are forward-looking. Words such as &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include statements about our business strategy, timeline and other goals, plans and prospects, including our commercialization plans respecting PEDMARK</i><sup style="font-size:9pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-size:12pt;font-style:italic;">/</i><i style="font-size:12pt;font-style:italic;">PEDMARQSI</i><sup style="font-size:9pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-size:12pt;font-style:italic;">, the market opportunity for and market impact of PEDMARK</i><sup style="font-size:9pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-size:12pt;font-style:italic;">/ </i><i style="font-size:12pt;font-style:italic;">PEDMARQSI</i><sup style="font-size:9pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-size:12pt;font-style:italic;">, its potential impact on patients and anticipated benefits associated with its use, future</i><i style="font-size:12pt;font-style:italic;"> commercial and regulatory milestone and royalty payments from Norgine,</i><font style="font-size:12pt;"> </font><i style="font-size:12pt;font-style:italic;">and potential access to further funding after the date of this release. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company&#8217;s business that could cause actual results to vary, including the risks and uncertainties that regulatory and guideline developments may change, scientific data and/or manufacturing capabilities may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak, protection offered by the Company&#8217;s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company&#8217;s products will not be as large as expected, the Company&#8217;s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, our ability to obtain necessary capital when needed on acceptable terms or at all, the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Company&#8217;s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2024. Fennec disclaims any obligation to update these forward-looking statements except as required by law.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><i style="font-size:12pt;font-style:italic;background:#ffffff;">For a more detailed discussion of related risk factors, please refer to our public filings available at&#160;</i><i style="font-size:12pt;font-style:italic;background:#ffffff;">www.sec.gov</i><i style="font-size:12pt;font-style:italic;background:#ffffff;">&#160;and&#160;</i><i style="font-size:12pt;font-style:italic;background:#ffffff;">www.sedar.com</i><i style="font-size:12pt;font-style:italic;background:#ffffff;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;background:#ffffff;">PEDMARK</font><sup style="font-size:9pt;vertical-align:top;background:#ffffff;">&#174;</sup><font style="font-size:12pt;background:#ffffff;"> </font><font style="font-size:12pt;">PEDMARQSI</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-size:12pt;"> </font><font style="font-size:12pt;background:#ffffff;">and Fennec</font><sup style="font-size:9pt;vertical-align:top;background:#ffffff;">&#174;</sup><font style="font-size:12pt;background:#ffffff;"> are registered trademarks of Fennec Pharmaceuticals Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;background:#ffffff;">&#169;2025 Fennec Pharmaceuticals Inc. All rights reserved. FEN-1604-v1</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;background:#ffffff;">For further information, please contact:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-size:12pt;font-weight:bold;background:#ffffff;">Investors:</b><font style="font-size:12pt;background:#ffffff;"><br></font><font style="font-size:12pt;">Robert Andrade</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Chief Financial Officer</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Fennec Pharmaceuticals Inc.</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">+1 919-246-5299</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-size:12pt;font-weight:bold;background:#ffffff;">Corporate and Media:</b><font style="font-size:12pt;background:#ffffff;"><br></font><font style="font-size:12pt;background:#ffffff;">Lindsay Rocco </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;background:#ffffff;">Elixir Health Public Relations</font><font style="font-size:12pt;background:#ffffff;"><br></font><font style="font-size:12pt;background:#ffffff;">+1 862-596-1304</font><font style="font-size:12pt;background:#ffffff;"><br></font><font style="font-size:12pt;background:#ffffff;">lrocco@elixirhealthpr.com</font></p><div style="margin-bottom:5pt;margin-top:15pt;width:25%;border-bottom:1px solid black;"></div><a name="endnote-2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">i</sup> Mody MD, Rocco JW, Yom SS, et al: Head and neck cancer. Lancet 398:2289-2299, 2021.</p><a name="endnote-3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">ii</sup> Rybak L. Mechanisms of Cisplatin Ototoxicity and Progress in Otoprotection. Current Opinion in Otolaryngology &amp; Head and Neck Surgery. 2007, Vol. 15: 364-369.</p><a name="endnote-4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">iii</sup> Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Trends Pharmacol Sci. 2013;34(8):458-469</p><a name="endnote-5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">iv</sup> Landier W. Ototoxicity and Cancer Therapy. <i style="font-style:italic;">Cancer</i>. June 2016 Vol. 122, No.11: 1647-1658<font style="background:#ffffff;">.</font></p><a name="endnote-6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">v</sup> Clemens E, van den Heuvel-Eibrink MM, Mulder RL, et al. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. <i style="font-style:italic;">Lancet Oncol</i>. 2019;20(1):e29-e41</p><a name="endnote-7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">vi</sup> <b style="font-weight:bold;">. </b>Bass JK, Knight KR, Yock TI, Chang KW, Cipkala D, Grewal SS. Evaluation and management of hearing loss in survivors of childhood and adolescent cancers: a report from the children&#8217;s oncology group. <i style="font-style:italic;">Pediatr Blood Cancer</i>. 2016;63(7):1152-1162.</p><a name="endnote-8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">vii</sup> Chattaraj A et al. Cisplatin-Induced Ototoxicity: A Concise Review of the Burden, Prevention, and Interception Strategies. <i style="font-style:italic;">JCO Oncol Pract</i>. 2023;19</p><a name="endnote-9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">viii</sup> Freyer DR et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. <i style="font-style:italic;">Lancet Oncol</i>. 2017;18(1):63-74.</p><a name="endnote-10"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">ix</sup> Rajput K, Edwards L, Brock P, Abiodun A, Simpkin P, Al-Malky G. Ototoxicity-induced hearing loss and quality of life in survivors of paediatric cancer<i style="font-style:italic;">. Int J Pediatr Otorhinolaryngol</i>. 2020;138:110401. doi:10.1016/j.ijporl.2020.110401</p><a name="endnote-11"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">x</sup> Bass JK, Knight KR, Yock TI, Chang KW, Cipkala D, Grewal SS. Evaluation and management of hearing loss in survivors of childhood and adolescent cancers: a report from the children&#8217;s oncology group. Pediatr Blood Cancer. 2016;63(7):1152-1162.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>fencf-20260220xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fencf-20260220xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !* (,# 2(  A$! Q$!_\0
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0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>fencf-20260220.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/20/2026 8:23:24 PM-->
<!--Modified on: 2/20/2026 8:23:24 PM-->
<xsd:schema targetNamespace="http://adherex.com/20260220" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:fencf="http://adherex.com/20260220">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://adherex.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="fencf-20260220_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="fencf-20260220_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>fencf-20260220_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/20/2026 8:23:24 PM-->
<!--Modified on: 2/20/2026 8:23:24 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>fencf-20260220_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/20/2026 8:23:24 PM-->
<!--Modified on: 2/20/2026 8:23:24 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="fencf-20260220.xsd#DocumentDocumentAndEntityInformation" roleURI="http://adherex.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://adherex.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_639072158044897343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_639072158044897343" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_639072158044897343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_639072158044897343" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_639072158044897343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_639072158044897343" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_639072158044897343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_639072158044897343" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_639072158044897343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_639072158044897343" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_639072158044902542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_639072158044902542" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_639072158044904703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_639072158044904703" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_639072158044904703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_639072158044904703" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_639072158044904703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_639072158044904703" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_639072158044904703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_639072158044904703" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_639072158044904703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_639072158044904703" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_639072158044904703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_639072158044904703" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_639072158044904703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_639072158044904703" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_639072158044904703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_639072158044904703" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_639072158044911390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_639072158044911390" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_639072158044911390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_639072158044911390" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_639072158044911390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_639072158044911390" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_639072158044911390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_639072158044911390" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_639072158044911390" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_639072158044911390" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_639072158044917327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_639072158044917327" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_639072158044924781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_639072158044924781" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_639072158044924781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_639072158044924781" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_639072158044924781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_639072158044924781" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 20, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 20,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-32295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FENNEC PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-0442384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">PO Box 13628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">68 TW Alexander Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Research Triangle Park<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">636-4530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares, no par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FENC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001211583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="fencf-20260220x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adherex.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>fencf-20260220.xsd</File>
    <File>fencf-20260220_lab.xml</File>
    <File>fencf-20260220_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="fencf-20260220x8k.htm">fencf-20260220x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "fencf-20260220x8k.htm": {
   "nsprefix": "fencf",
   "nsuri": "http://adherex.com/20260220",
   "dts": {
    "schema": {
     "local": [
      "fencf-20260220.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "fencf-20260220_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fencf-20260220_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "fencf-20260220x8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://adherex.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fencf-20260220x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fencf-20260220x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://adherex.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001104659-26-018128-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-018128-xbrl.zip
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MLAEEZ9E@GXMUM$/GA+-5AT9F K?M93N0.W5=Y+-R%YMQW2WX@?06!GD+Z3!
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MX*"6V:0&IM2XV1L-::'>D42LW@(2^7&R<[4S7$*Q)AS&#)U'2.O)X/57@>J
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M.@SIPWIGI(&C"%M,3("_211\81/[8.;CG@$FF_0@+<%<CNL1.T%</!3='U"
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MSGIB\/GDY-/IV<'Q!W&VOR<TUCA.))&)Z!WOBO[AP3&-(#X/]L2G]^)$^=C
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M,4,UJPDS'=*$FG@.:D[[K# EN4L2XI(<\\@GX!G+H0F04+TM2[M.%G8=X\"
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M4$L! A0#%     @ 2X!47*#WQU*!!0  ,SX  !8              ( !-0,
M &9E;F-F+3(P,C8P,C(P7VQA8BYX;6Q02P$"% ,4    " !+@%1<;!T1&[,$
M  !(*   %@              @ 'J"   9F5N8V8M,C R-C R,C!?<')E+GAM
M;%!+ 0(4 Q0    ( $N 5%S&P)L/C!<  $'1   5              "  =$-
M  !F96YC9BTR,#(V,#(R,'@X:RYH=&U02P$"% ,4    " !+@%1<B'4F2^\?
M  #IH@  &0              @ &0)0  9F5N8V8M,C R-C R,C!X97@Y.60Q
:+FAT;5!+!08     !0 % %(!  "V10     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>fencf-20260220x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="fencf-20260220.xsd" xlink:type="simple"/>
    <context id="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001211583</identifier>
        </entity>
        <period>
            <startDate>2026-02-20</startDate>
            <endDate>2026-02-20</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Tc_jysIPrjWQUmNBdilL3KD_g_1_1">0001211583</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Tc_FJcPCylevEq7qYpIC16WvQ_2_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Narr_vGxwr5Ih10a4zmplVODjDw">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Narr_nFwD3d3YOUm9qWid6O9SJA">2026-02-20</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Narr_kjci57_x1Eeh-Ho9f8lm2Q">FENNEC PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityFileNumber
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Narr_Y9Dm7YPUjU2eNNkX6i0Qjg">001-32295</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Tc_-ww0H-dDiUWR-DJiR5xinw_1_0">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Tc_6p_mKrcc80ahMQHuoIGM0Q_1_2">20-0442384</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Narr_AWNs0ZUP006cF3rLI1zqLw">PO Box 13628</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Narr_hrQtaZdFd0CTs4mRenxE1g">68 TW Alexander Drive</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Narr_aKhZ2Y1Id0ik4L78TUCWtQ">Research Triangle Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Narr_p-qFiLksNk6ENvxJ80NCbw">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Tc_iZfK511Yr0uNIyKC9_Aq0Q_1_2">27709</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Narr_Qx9CzwU8JEmfvqfWMVAgMQ">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Narr_tzHqPynZR0qIIfl0QNyyiw">636-4530</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Tc_2nK8ANSfrk-GDcv2Wm9qFw_1_1">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Tc_PSfcH160FESbJQyUWEsUbg_1_1">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Tc_UsGs3plNJkWq9yZxenpSZQ_1_1">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Tc_joA9xlOGcUGwLNDJc8CRJQ_1_1">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Tc_G_H7yTn_606kgQL1W71HWw_2_0">Common shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Tc_9hmkBlNIJ0iZhwHUYTQF2A_2_1">FENC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Narr_4kj_swpFQEGc_mZoyAkKSA">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_2_20_2026_To_2_20_2026_VFD4xf_ztUmWM2KzXyjLGw"
      id="Narr_wcDTKnRweESa8yfmnC8spQ">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
